Case Details
- Citation: [2017] SGCA 45
- Case Number: Civil Appeal No 121 of 2016
- Date of Decision: 1 August 2017
- Court: Court of Appeal of the Republic of Singapore
- Coram: Sundaresh Menon CJ; Chao Hick Tin JA; Andrew Phang Boon Leong JA; Judith Prakash JA; Tay Yong Kwang JA
- Plaintiff/Applicant: Warner-Lambert Company LLC
- Defendant/Respondent: Novartis (Singapore) Pte Ltd
- Procedural Origin: Appeal from the High Court decision reported at [2016] 4 SLR 252 (Warner-Lambert Co LLC v Novartis (Singapore) Pte Ltd)
- Key Procedural Event: Warner-Lambert sought leave to amend its patent claims (SUM 4136 of 2015) after Novartis challenged validity
- Underlying Suit: Suit 390 of 2015
- Subject Matter of Patent: Pharmaceutical patent owned by Warner-Lambert claiming a monopoly over the use of pregabalin for the treatment of pain; product “Lyrica” approved by the Health Sciences Authority (HSA)
- Patent Filing and Grant: Filed 16 July 1997; granted in Singapore on 23 May 2000
- Expiry of Statutory Protection: 16 July 2017 (20-year protection)
- Medicines Regulatory Trigger: 23 March 2015 notification by Novartis to Warner-Lambert under s 12A(3)(a) of the Medicines Act
- High Court Decision on Amendment: Dismissed Warner-Lambert’s application to amend; held amendments would extend protection and that there was undue delay
- Issues on Appeal: Whether the proposed amendments should be allowed; whether they would extend protection; whether discretion should be exercised despite delay; broader observations on subsequent medical uses and “Swiss-style” claims
- Judgment Length: 26 pages; 13,949 words
- Counsel: Stanley Lai Tze Chang SC, Gloria Goh En-Ci and Clara Tung Yi Lin (Allen & Gledhill LLP) for the appellant; Prithipal Singh s/o Seva Singh, Suhaimi Bin Lazim and Chow Jian Hong (Mirandah Law LLP) for the respondent; Professor David Llewelyn (School of Law, Singapore Management University) as amicus curiae
- Legal Areas: Patents and Inventions — Industrial application; Patents and Inventions — Novelty
- Statutes Referenced: Patents Act (Cap 221, 2005 Rev Ed); Medicines Act (Cap 176, 1985 Rev Ed); UK Patents Act 1977; UK Patents Act 1977 (as amended in 2004); A of the UK Patents Act 1977
- Cases Cited: [2017] SGCA 30; [2017] SGCA 45; [2016] 4 SLR 252 (reported High Court decision referenced in the appeal narrative)
Summary
Warner-Lambert Company LLC v Novartis (Singapore) Pte Ltd [2017] SGCA 45 concerned a pharmaceutical patent dispute arising from regulatory steps taken by Novartis to obtain product licences from Singapore’s Health Sciences Authority (HSA) for pregabalin products. Warner-Lambert’s patent claimed protection over the use of pregabalin for treating pain, and the company sought to prevent Novartis from obtaining licences on the basis that the patent would be infringed by the acts contemplated in the licence applications. Novartis, in turn, challenged the patent’s validity and sought revocation.
The Court of Appeal ultimately dismissed Warner-Lambert’s appeal against the High Court’s refusal to allow amendments to the granted patent claims. The appellate court agreed that the proposed amendments would extend the scope of protection conferred by the patent and that the court should not exercise its discretion to permit the amendments because of Warner-Lambert’s undue delay in seeking them. Although the appeal was not strictly necessary to decide certain broader patent-law questions, the Court took the opportunity to make observations on the protection of subsequent medical uses of known substances and the validity of “Swiss-style” claims under Singapore’s Patents Act.
What Were the Facts of This Case?
The dispute arose in Suit 390 of 2015 between two major pharmaceutical companies. Warner-Lambert owned a Singapore patent (the “Patent”) claiming a monopoly over the use of pregabalin for the treatment of pain. Under the Patent, Warner-Lambert manufactured and distributed “Lyrica” in Singapore. Lyrica had HSA approval for treating conditions including neuropathic pain and chronic pain disorders, such as fibromyalgia. The Patent was filed on 16 July 1997 and granted on 23 May 2000, meaning its 20-year statutory protection expired on 16 July 2017.
On 23 March 2015, Warner-Lambert received notification from Novartis of Novartis’ applications to the HSA for product licences for pregabalin products. The notification was made pursuant to s 12A(3)(a) of the Medicines Act. In that notification, Novartis asserted that the Patent would not be infringed by the acts for which the product licences were sought. In response, on 21 April 2015, Warner-Lambert commenced Suit 390 seeking, among other relief, a declaration that the Patent would be infringed if Novartis carried out the acts contemplated by its licence applications.
As part of its litigation posture, Warner-Lambert indicated on 5 May 2015 that it intended to amend the Patent. Novartis filed its defence and counterclaim on 2 June 2015, seeking revocation of the Patent on the ground that the Patent was invalid. The invalidity argument focused on the statutory exclusion relating to methods of treatment. Specifically, Novartis argued that the Patent claimed a monopoly over methods of treatment of the human or animal body, which Singapore patent law does not permit. The Patents Act provides that an invention of a method of treatment by surgery or therapy, or diagnosis practised on the human or animal body, is not to be taken as capable of industrial application (s 16(2)). Since industrial application is a requirement for patentability (s 13(1)), such claims are excluded from patentability.
On 26 August 2015, Warner-Lambert applied for leave to amend the Patent (SUM 4136 of 2015) under s 83(1) of the Patents Act. The amendments were designed to cure invalidity in the granted claims, which Warner-Lambert accepted “clearly contradicted” s 16(2). The High Court dismissed the amendment application. It reasoned that allowing the amendments would extend the scope of protection of the Patent, and it also found that Warner-Lambert had delayed too long in seeking amendments, which justified refusing the court’s discretion. Warner-Lambert appealed, but the Court of Appeal dismissed the appeal.
What Were the Key Legal Issues?
The core issue on appeal was whether the Court should permit Warner-Lambert to amend its patent claims. Under the Patents Act framework for amendments, the court must consider whether the proposed amendments are permissible and whether they would offend statutory constraints, including whether they would extend the scope of protection conferred by the granted patent. The High Court had found that the amendments would extend protection, and the Court of Appeal agreed.
A second key issue concerned the exercise of judicial discretion in amendment matters. Even where amendments are conceptually aimed at curing invalidity, the court may refuse leave if the patentee has acted with undue delay. The High Court had held that Warner-Lambert’s delay was undue and that it was “lengthy and inexplicable”, and the Court of Appeal upheld that approach. Accordingly, the appeal required the appellate court to assess both the legal effect of the amendments and whether the patentee’s conduct warranted refusal.
Although not strictly necessary for the resolution of the amendment appeal, the Court of Appeal also addressed broader patent-law questions raised by the parties and the amicus curiae. These observations related to (i) the protection of subsequent medical uses of known substances and (ii) the validity of “Swiss-style” claims under Singapore’s Patents Act. These issues matter because pharmaceutical patent strategies often rely on claim formats that attempt to capture new therapeutic uses while using known compounds.
How Did the Court Analyse the Issues?
The Court of Appeal began by situating the dispute within Singapore’s statutory scheme for patentability and the specific “method of treatment exclusion”. Section 16(2) of the Patents Act deems methods of treatment and diagnosis practised on the human or animal body incapable of industrial application. The Court explained that this exclusion is based on a legal fiction: methods of treatment and diagnosis are treated as not capable of industrial application, even though they may be carried out in an industrial or systematic context. The Court endorsed the rationale articulated by the High Court, including socio-ethical and public health considerations, namely that it is not in the public interest for medical practice to be controlled by a few through patent licensing requirements.
At the same time, the Court emphasised the statutory clarification in s 16(3): products invented for use in a method of treatment are not caught by the exclusion. This distinction is crucial in pharmaceutical patent law. It effectively “compels” applicants to focus claims on the medicinal product itself (or its use as a product) rather than on the method of treatment as such. The Court also noted that s 16 is in pari materia with s 4A of the UK Patents Act 1977 (as amended in 2004), reinforcing that the Singapore provision reflects a broader international approach to excluding medical methods from patentability.
Against this statutory backdrop, the Court assessed Warner-Lambert’s proposed amendments. The High Court had found that the amendments, if granted, would extend the scope of protection. The Court of Appeal agreed. While the judgment extract provided does not reproduce the full claim-by-claim analysis, the appellate conclusion indicates that the amendments were not merely clarificatory or corrective in a way that preserved the original protective boundaries. Instead, they would broaden what the patent would cover, which is impermissible in the amendment context because it undermines the legal certainty expected of granted patent rights and potentially prejudices third parties who rely on the scope of the granted claims.
The Court also upheld the High Court’s discretion-based refusal grounded in undue delay. Amendment applications in patent litigation are not purely technical exercises; they are subject to equitable and procedural considerations. The Court accepted that Warner-Lambert’s delay was “lengthy and inexplicable” and that this delay warranted refusal. The reasoning reflects a policy that patentees should act promptly to align their claims with statutory requirements and to avoid strategic or tactical amendment after validity challenges have crystallised. In practical terms, allowing late amendments that broaden protection would risk unfairness to competitors and would dilute the integrity of the patent examination and opposition/revocation processes.
Finally, the Court’s observations on subsequent medical uses and “Swiss-style” claims show the Court’s awareness of the evolving pharmaceutical patent landscape. “Swiss-style” claims typically attempt to claim a second medical use of a known substance by framing the claim as a specific therapeutic use. The Court indicated that these issues had not been fully considered by Singapore courts and therefore offered guidance for future cases. While the Court did not need to decide these questions to dispose of the appeal, its commentary signals that Singapore courts will scrutinise claim formats against the statutory method-of-treatment exclusion and the industrial application requirement.
What Was the Outcome?
The Court of Appeal dismissed Warner-Lambert’s appeal and upheld the High Court’s refusal to grant leave to amend the Patent. The practical effect is that Warner-Lambert remained unable to cure the invalidity concerns by way of the proposed amendments, and Novartis’s challenge to the Patent’s validity remained on foot in the underlying dispute.
In addition, the Court’s dismissal meant that the Patent’s granted claims could not be reshaped to avoid the s 16(2) exclusion in the manner Warner-Lambert sought. The decision therefore reinforces both the substantive limits on patent claim scope in the medical field and the procedural expectation that patentees must pursue amendments promptly and within the boundaries of permissible claim modification.
Why Does This Case Matter?
This decision is significant for practitioners because it clarifies the interaction between (i) Singapore’s method-of-treatment exclusion and (ii) the limits on patent amendments. The Court’s endorsement of the High Court’s approach underscores that amendments are not automatically allowed simply because they are intended to address statutory invalidity. The court will examine whether amendments extend the scope of protection and will refuse amendments that broaden the patent’s legal effect.
Equally important, the case highlights that undue delay can be fatal to amendment applications. Patent litigation often involves complex technical and regulatory timelines, but this judgment signals that patentees should not wait until after validity challenges are raised to seek claim changes. For pharmaceutical companies, where claim strategy is frequently refined over time, the decision provides a cautionary message: amendment applications must be timely, and they must be crafted so that they do not expand protection beyond what was originally granted.
From a broader doctrinal perspective, the Court’s observations on subsequent medical uses and “Swiss-style” claims are likely to influence future patent drafting and litigation. Pharmaceutical innovation frequently involves new therapeutic indications for known compounds. The Court’s willingness to address these topics, even obiter, suggests that Singapore courts will continue to develop the law on how such claims fit within the statutory exclusion for methods of treatment. Lawyers advising on claim construction, infringement, and validity will therefore need to consider not only the substance of the invention but also the claim format and its compliance with s 16’s industrial application requirement.
Legislation Referenced
- Patents Act (Cap 221, 2005 Rev Ed), including:
- Section 13(1) (industrial application requirement)
- Section 16(2) (method of treatment exclusion; deemed not capable of industrial application)
- Section 16(3) (product invented for use in method of treatment not caught by the exclusion)
- Section 83(1) (amendment of patent)
- Section 84(3)(b) (as referenced in the appeal narrative regarding extension of protection)
- Medicines Act (Cap 176, 1985 Rev Ed), including:
- Section 12A(3)(a) (notification mechanism for product licence applications)
- UK Patents Act 1977, including:
- Section 4A (noted as in pari materia with Singapore’s s 16)
- Section A (as referenced in the metadata)
Cases Cited
- [2017] SGCA 30
- [2017] SGCA 45
- Warner-Lambert Co LLC v Novartis (Singapore) Pte Ltd [2016] 4 SLR 252
- CYGNUS/Diagnostic method (G 1/04) [2006] EPOR 15
Source Documents
This article analyses [2017] SGCA 45 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.